Hi MOZZ - 33.5% pa since 2016 is great for sure, My start date in 2018 still very good. I like your confidence going forward, but for me, PAR is now "hold" not "buy" because 2022 is crunch time. Just too many uncertainties. I know pharma very well. They want to acquire technologies, but not the actual small cap company itself if they can avoid it, so I don't worry about us being acquired. Licensing deals generally take at least 6 months & a year is not uncommon. PAR will want max. cash up front in a licensing deal and pharma will want to back load with min. upfront cash so if PR or the new CEO does a deal, the crucial question is how much actual cash will we have in hand by say 4Q '22 to fund the pivotal P3 Zilosul trial in '23-'25?. Trying to get >$60 mil up front cash from pharma by Q4 could be a big ask, but at least if a respectable deal is done with pharma it could lift the SP & make a CR easier. If a deal is not done with pharma in '22, a CR will be very hard yakka in my opinion. Also, any more hiccups and the SP will be on a slippery slope. I suspect the shorters are punting that these uncertainties will keep buyers away until the end of '22. The new CEO needs to deliver a deal with significant cash in the next 12 month IMO or the multi bagger we all hope for is in serious jeopardy. I remain hopeful, but cautious.
PS: IMO Rennie has lost too much credibility which is probably one reason the board encouraged him to step aside. Nearly two years ago he gave us a list of newsflow for the next 12 months including high hopes for a pharma deal. Very little of that has actually been delivered. The new CEO, must tell it like it is; no hype or spin. Whoever he/she is MUST be 1st class and MUST be on board ASAP. This is urgent.
- Forums
- ASX - By Stock
- PAR
- PAR and the Deal, what do we need?
PAR and the Deal, what do we need?, page-5
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M |
Open | High | Low | Value | Volume |
21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 429247 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 13806 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 389247 | 0.200 |
8 | 133607 | 0.195 |
17 | 238789 | 0.190 |
4 | 92160 | 0.185 |
8 | 122773 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 13806 | 2 |
0.215 | 28509 | 1 |
0.220 | 59615 | 6 |
0.225 | 28604 | 2 |
0.230 | 16334 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |